A practical evaluation guide for pharma directors assessing agency capabilities, pre-launch readiness, and strategic fit — before signing.
Executive Summary (TL;DR)
The Capability Gap: Most pharma directors select a launch agency on credentials and prior relationships alone — missing the cross-functional depth that determines whether a molecule reaches its commercial ceiling.
The Evaluation Strategy: A structured RFP built around go-to-market strategy, regulatory navigation, omnichannel HCP engagement, and India-specific market knowledge separates genuine launch partners from generalist agencies.
The Imperative: Brands that win at launch treat agency selection as a strategic decision, not a procurement exercise — and start that evaluation at least 18 months before commercialisation.
Pharma & Life Sciences Practice • Brand Strategy Intelligence
A cross-functional pharma launch team reviews go-to-market strategy materials with their agency partner ahead of commercialisation.
Most pharma directors select a pharma product launch agency the way they would hire a vendor — on the strength of prior relationships, a well-designed credentials deck, and a competitive day rate. That model consistently produces underperforming launches. An agency that can execute tactical deliverables is not the same as one that can co-architect the pre-launch strategy. The distinction matters enormously, especially in the first 12 months on market when launch trajectories are set and rarely recovered.
The stakes have never been higher. Global pharmaceutical launches now face compressed timelines, more sceptical payer environments, and a prescribing community that expects personalised, evidence-led engagement from day one. Indian brands face an additional layer of complexity — DCGI (Drugs Controller General of India) regulatory pathways, a fragmented distribution landscape, and a bifurcated market that serves both originator brands and branded generics simultaneously.
This guide gives pharma directors a structured framework for evaluating, briefing, and selecting a launch partner capable of building the pre-launch strategy their asset actually requires.
The term ‘pharma launch agency’ covers a wide spectrum. At one end sits the traditional healthcare advertising agency — strong on brand identity, visual communication, and campaign execution. At the other end sits the full-service pre-launch strategy partner — one that enters the engagement well before regulatory approval, shapes the go-to-market architecture, aligns medical and commercial workstreams, and builds the brand foundation the product needs before the first prescription is written.
Most agencies position themselves in the second category. Few actually operate there. A genuine pre-launch strategy partner does several things that a campaign agency does not. It maps the target product profile (TPP) against payer and prescriber barriers, builds a medical education strategy that runs parallel to the promotional plan, and designs the omnichannel HCP (healthcare professional) engagement model before any creative brief is written. It owns the strategic narrative — the clinical differentiators translated into brand positioning — and stress-tests that narrative against competitive intelligence, all before a single detail aid is produced.
It also knows when to slow down. Launch readiness is not just a marketing milestone. It includes regulatory clearance timelines, formulary access trajectories, MSL (Medical Science Liaison) deployment readiness, and supply chain confidence. A capable pre-launch strategy partner asks about all of these before it promises a launch date — and builds the internal alignment to address them. It is the standard OneAlphaMed’s brand strategy practice applies from the first brief.
"Pharmaceutical products that miss Year 1 revenue targets rarely fail because of the molecule — approximately 70% of launch underperformance traces back to misaligned commercial infrastructure, inadequate HCP engagement strategy, or agency capabilities that did not match the asset's real-world barriers to adoption."
A strong go-to-market strategy for pharma is not a campaign plan with a brand story attached. It is a sequenced commercial architecture that connects asset evidence to prescriber behaviour, payer access, and patient journey — across every relevant channel.
Excellence in go-to-market strategy begins upstream. The agency should enter the engagement at the TPP stage — helping the brand team understand which clinical differentiators carry commercial weight and which carry regulatory risk when over-amplified. From there, a rigorous GTM strategy addresses four sequenced questions: Who are the highest-value prescriber segments? Which payer archetypes control access? What does the patient pathway look like? And how does the communication plan reach these audiences with differentiated messaging?
The agency should also own the channel architecture decision — which touchpoints to prioritise, in what sequence, and with what frequency. Omnichannel execution in pharma is not synonymous with “digital first.” In many therapeutic areas, personal promotion through well-briefed field teams remains the most effective driver of early prescribing behaviour. The best agencies follow the evidence on what moves prescribers in the specific disease area.
Evaluating an agency purely on past campaign work misses the structural capabilities that make or break a launch. When assessing a pharma product launch agency, directors should audit the following dimensions directly.
The agency team must demonstrate working fluency with CDSCO standards, promotional compliance frameworks, and the distinction between promotional and medical communication. Agencies that cannot articulate what “off-label” means in practice introduce commercial and reputational risk at scale.
Genuine cross-functional launch support means the agency can work alongside Medical Affairs, Market Access, and commercial leadership without requiring each team to manage a separate vendor relationship. Fragmented agency models are one of the most common and costly structural errors in pharma launch planning.
Does the agency use real-world prescribing data or specialist CRM analytics to inform targeting? At OneAlphaMed, this data infrastructure is built into the brand strategy engagement from day one — so targeting decisions are evidence-led, not assumption-driven.
Explore how OneAlphaMed structures integrated launch strategy for pharma brands
Explore Brand Strategy and Product Launch →Indian pharma brands operate in a commercial environment that most global launch agencies are structurally unequipped to navigate. Selecting an agency without India-specific capability is a structural mismatch.
DCGI approval timelines differ meaningfully from FDA or EMA frameworks. An agency advising on launch sequencing must understand what is permissible in Indian promotional practice and how activity interfaces with UCPMP compliance obligations.
India’s market runs on a branded generics model where originator brands compete against innovators and dense fields of branded equivalents. An agency must understand the role of quality signals and physician trust in a market where price is always visible but rarely the only decision variable.
A significant proportion of India’s prescribing volume sits outside metro markets. Agencies that design strategies exclusively around Delhi or Mumbai underestimate the commercial opportunity in Tier 2 and Tier 3 cities—and the distinct relationship infrastructure those markets require.
A brief that asks for “credentials and case studies” does not generate enough signal to differentiate a strategic partner from a capable executor.
A rigorous RFP for a pharma launch partner should specify:
Evaluation panels should include commercial, medical affairs, and market access perspectives — not just marketing. Scoring should weight strategic capability alongside creative track record, and conflict-of-interest checks should be standard, not optional.
A pharma product launch agency selection is one of the highest-leverage commercial decisions a brand team makes. The agency a company brings into the room at 18 months pre-launch will shape the commercial narrative, the HCP engagement model, and the payer access strategy that carry the asset through its first year on market.
The pharma brands winning at launch today treat agency selection as a strategic act. They weight India-specific market fluency and bring the agency into the room early enough to shape the pre-launch strategy rather than execute a plan someone else designed. That is what a pre-launch strategy partner looks like — and it is the standard every launch-stage brand should hold.
OneAlphaMed’s brand strategy practice partners with pharma teams at TPP stage — building pre-launch positioning and go-to-market architecture before the campaign brief is written. See how we approach Brand Strategy and Product Launch →
A pharma product launch agency co-develops the pre-launch strategy for a new product — including go-to-market architecture, HCP engagement strategy, medical communication, omnichannel planning, and launch readiness assessment. The strongest agencies enter the engagement at least 18 months before launch day, not at campaign brief stage.
Ideally at Phase 3 clinical stage or earlier — before the regulatory filing, not after it. This allows the agency to contribute to positioning based on evolving clinical evidence, shape the medical education narrative alongside the promotional plan, and identify payer access requirements before launch sequencing is locked.
A rigorous agency RFP should include the therapeutic area context, the asset's regulatory stage, key commercial questions that require agency input, the internal team structure the agency will work with, and a paid live diagnostic brief. The brief should reveal strategic thinking, not just creative execution or credentials.
Indian pharma launches require agency fluency in DCGI regulatory frameworks, UCPMP compliance, the branded generic competitive environment, regional distribution dynamics, and HCP engagement strategies calibrated for Tier 2 and Tier 3 city markets. Global agencies without India-specific market knowledge routinely underestimate these structural differences.
+91 9811660635
info@onealphamed.com
2414, Ground Floor, Aravali Vihar, Sector 49 Faridabad, Haryana – 121001 India
Copyright © 2026 OneAlphaMed. All Rights Reserved.
